Clinical and methodologic considerations with regard to a trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: comment on the reanalysis by Maher et al

被引：1
|
作者：
Bredemeier, Markus [1 ]
机构：
[1] Hosp Nossa Senhora Conceicao, Conceicao Hosp Grp, Porto Alegre, RS, Brazil
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年
关键词：
D O I：
10.1002/art.41893
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303
  • [42] Lung transplantation for systemic sclerosis-associated interstitial lung disease
    Le Pavec, J.
    Launay, D.
    Cottin, V.
    Reynaud-Gaubert, M.
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 : E73 - E79
  • [43] Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease
    Khanna, Dinesh
    Tashkin, Donald
    Wells, Athol
    Goldin, Jonathan
    Lubell, Martin
    Wax, Steven
    Damian, Doris
    Denton, Christopher
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [44] Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
    Hoffmann-Vold, Anna-Maria
    Allanore, Yannick
    Alves, Margarida
    Brunborg, Cathrine
    Airo, Paolo
    Ananieva, Lidia P.
    Czirjak, Laszlo
    Guiducci, Serena
    Hachulla, Eric
    Li, Mengtao
    Mihai, Carina
    Riemekasten, Gabriela
    Sfikakis, Petros P.
    Kowal-Bielecka, Otylia
    Riccardi, Antonella
    Distler, Oliver
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02) : 219 - 227
  • [45] THE STUDY OF NINTEDANIB EFFICACY IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
    Koneva, Olga A.
    Garzanova, Liudmila
    Ananyeva, Lidia
    Ovsyannikova, Olga
    Starovoytova, Mayya
    Desinova, Oxana
    Shayakhmetova, Rushana
    CHEST, 2023, 164 (04) : 5480A - 5481A
  • [46] Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease (December, 10.1080/14397595.2019.1696505, 2019)
    Kuwana, Masataka
    Azuma, Arata
    MODERN RHEUMATOLOGY, 2020, 30 (02) : 225 - 231
  • [47] EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN SUBGROUPS BY DISEASE ACTIVITY INDEX
    Herrick, A.
    Pope, J.
    Carreira, P.
    Miede, C.
    Alves, M.
    Allanore, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 963 - 963
  • [48] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS-ON Trial
    Highland, K. B.
    Vonk, M. C.
    Azuma, A.
    Mayes, M. D.
    Gahlemann, M.
    James, A.
    Kohlbrenner, V.
    Allanore, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [49] Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo
    Daoussis, Dimitrios
    Andonopoulos, Andrew P.
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (06) : 841 - 842
  • [50] Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo
    Dimitrios Daoussis
    Andrew P. Andonopoulos
    Rheumatology International, 2011, 31 : 841 - 842
12345